Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | In stock | $ 38.00 | |
100 mg | In stock | $ 50.00 | |
200 mg | In stock | $ 70.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 45.00 |
Description | Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist. |
In vivo | In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete cytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α[1]. |
Synonyms | R 837, S-26308 |
Molecular Weight | 240.3 |
Formula | C14H16N4 |
CAS No. | 99011-02-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.4 mg/ml (10 mM), Sonification is recommended
H2O: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Imiquimod 99011-02-6 Autophagy Immunology/Inflammation Microbiology/Virology SARS-CoV TLR HSV Bowen's R-837 intraepithelial carcinoma basal ,cell inhibit Toll-like Receptor (TLR) contagiosum molluscum S26308 keratosis vulvar Herpes simplex virus R 837 warts actinic infection disease R837 squamous human cell S 26308 nongenital SARS coronavirus neoplasia S-26308 papillomavirus Inhibitor inhibitor